Laryngopharyngeal Reflux Treatment Guidelines

Introduction to Treatment

The American Academy of Otolaryngology-Head and Neck Surgery recommends esomeprazole 40 mg twice daily for a minimum of 16 weeks for patients with laryngopharyngeal reflux and posterior laryngeal edema, as this represents the most aggressive acid suppression strategy supported by guideline evidence for chronic laryngitis with documented laryngoscopic findings 1, 2, 3

The American Academy of Otolaryngology-Head and Neck Surgery guidelines specifically support twice-daily PPI therapy for patients with hoarseness and signs of chronic laryngitis, defined as erythema, edema, redundant tissue, and/or surface irregularities of the posterior laryngeal mucosa, arytenoid mucosa, or vocal folds 1, 2, 3, 4
Research evidence demonstrates that esomeprazole 40 mg twice daily was the specific dosage studied in randomized controlled trials for patients with laryngoscopic evidence of laryngitis including posterior laryngeal mucosa abnormalities 1, 2, 3

A minimum treatment duration of 16 weeks is necessary, as guideline evidence shows that laryngeal findings and symptoms require longer treatment periods than typical GERD 1, 2

The absence of esophagitis on upper endoscopy does not preclude laryngopharyngeal reflux as the etiology, as extraesophageal manifestations can occur without esophageal mucosal injury 1, 2, 3
Normal EGDS actually supports the diagnosis of isolated laryngopharyngeal reflux rather than typical GERD, making empiric therapy with twice-daily PPIs for 2-3 months a pragmatic clinical strategy according to the American Gastroenterological Association 5

The evidence for PPI efficacy in laryngopharyngeal reflux is mixed, with the highest quality randomized trial showing no benefit in symptom scores or quality of life, though laryngoscopic findings did improve 1, 2, 3
Long-term PPI use carries risks including impaired calcium absorption with increased hip fracture risk in older adults, dose-dependent vitamin B12 deficiency, iron deficiency anemia, and increased risk of pancreatitis 1, 2, 4

For responders, attempt to de-escalate to once-daily dosing after 4-6 months of symptom control, as maintenance therapy requirements for laryngopharyngeal reflux are not well-established 7